Dronabinol Is a Safe Long-Term Treatment Option for Neuropathic Pain Patients
Open accessThe DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Abstract
Treatment of neuropathic pain (NP) symptoms associated with multiple sclerosis (MS) is frequently insufficient. Yet, cannabis is still rarely offered for treatment of pain. This clinical trial aimed at showing the positive benefit-risk ratio of dronabinol. Two hundred forty MS patients with central NP entered a 16-weeks placebo-controlled phase-III study followed by a 32-weeks open-label period. One hundred patients continued therapy for overall up to 119 weeks. Primary endpoint was change of pain intensity on the 11-point Numerical Rating Scale over a 16-weeks treatment period. Safety was assessed on the basis of adverse reactions (ARs), signs of dependency and abuse. Pain intensity during 16-weeks dronabinol and placebo treatment was reduced by 1.92 and 1.81 points without significant difference in between (p = 0.676). Although the proportion of patients with ARs was higher under dronabinol compared to placebo (50.0 vs. 25.9%), it decreased during long-term use of dronabinol (26%). No signs of drug abuse and only one possible case of dependency occurred. The trial results demonstrate that dronabinol is a safe long-term treatment option.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
McDonald, W. I., Compston, A., Edan, G., Goodkin, D., Hartung, H., Lublin, F. D., McFarland, H. F., Paty, D. W., Polman, C. H., Reingold, S. C., et al. (2001) · Annals of Neurology · doi:10.1002/ana.1032 · Cited by 6,969
Farrar, J. T., Young, J. P., LaMoreaux, L., Werth, J. L., & Poole, M. R. (2001) · Pain · doi:10.1016/s0304-3959(01)00349-9 · Cited by 5,808
Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis
Finnerup, N. B., Attal, N., Haroutounian, S., McNicol, E., Baron, R., Dworkin, R. H., Gilron, I., Haanpää, M., Hansson, P., Jensen, T. S., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70251-0 · Cited by 3,980
Treede (2008) · doi:10.1212/01.wnl.0000282763.29778.59 · Cited by 2,746
Psychosomatic medicine in Germany: more timely than ever
Zipfel, S., Herzog, W., Kruse, J., & Henningsen, P. (2016) · Psychotherapy and Psychosomatics · doi:10.1159/000447701 · Cited by 2,323
The Endocannabinoid System as an Emerging Target of Pharmacotherapy
Pacher, P., Bátkai, S., & Kunos, G. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.2 · Cited by 2,077
Dworkin, R. H., O'Connor, A. B., Audette, J., Baron, R., Gourlay, G. K., Haanpää, M. L., Kent, J. L., Krane, E. J., LeBel, A. A., Levy, R. M., et al. (2010) · Mayo Clinic Proceedings · doi:10.4065/mcp.2009.0649 · Cited by 1,325
Bullinger, M. (1995) · Social Science & Medicine · doi:10.1016/0277-9536(95)00115-n · Cited by 763
Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis
Rog, D. J., Nurmikko, T. J., Friede, T., & Young, C. A. (2005) · Neurology · doi:10.1212/01.wnl.0000176753.45410.8b · Cited by 679
The placebo response in medicine: minimize, maximize or personalize?
Enck, P., Bingel, U., Schedlowski, M., & Rief, W. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3923 · Cited by 671
Edlund, M. J., Martin, B. C., Russo, J. E., DeVries, A., Braden, J. B., & Sullivan, M. D. (2014) · The Clinical Journal of Pain · doi:10.1097/ajp.0000000000000021 · Cited by 510
Svendsen, K. B., Jensen, T. S., & Bach, F. W. (2004) · BMJ · doi:10.1136/bmj.38149.566979.ae · Cited by 500
Pain associated with multiple sclerosis: Systematic review and proposed classification
O’Connor, A. B., Schwid, S. R., Herrmann, D. N., Markman, J. D., & Dworkin, R. H. (2008) · Pain · doi:10.1016/j.pain.2007.08.024 · Cited by 498
Response expectancies in placebo analgesia and their clinical relevance
Pollo, A., Amanzio, M., Arslanian, A., Casadio, C., Maggi, G., & Benedetti, F. (2001) · Pain · doi:10.1016/s0304-3959(01)00296-2 · Cited by 442
Siddall, P. J., Cousins, M. J., Otte, A., Griesing, T., Chambers, R., & Murphy, T. K. (2006) · Neurology · doi:10.1212/01.wnl.0000244422.45278.ff · Cited by 398
Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up
Zajicek, J. P. (2005) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2005.070136 · Cited by 335
The Therapeutic Potential of Cannabis and Cannabinoids
Grotenhermen, F., & Müller-Vahl, K. (2012) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2012.0495 · Cited by 307
Langford, R. M., Mares, J., Novotna, A., Vachova, M., Novakova, I., Notcutt, W., & Ratcliffe, S. (2013) · Journal of Neurology · doi:10.1007/s00415-012-6739-4 · Cited by 298
Nonopioid placebo analgesia is mediated by CB1 cannabinoid receptors
Benedetti, F., Amanzio, M., Rosato, R., & Blanchard, C. (2011) · Nature Medicine · doi:10.1038/nm.2435 · Cited by 289
Gabapentin Is a First Line Drug for the Treatment of Neuropathic Pain in Spinal Cord Injury
Levendoğlu, F., Öğün, C. Ö., Özerbil, Ö., Öğün, T. C., & Uğurlu, H. (2004) · Spine · doi:10.1097/01.brs.0000112068.16108.3a · Cited by 267
Vranken, J. H., Dijkgraaf, M. G. W., Kruis, M. R., van der Vegt, M. H., Hollmann, M. W., & Heesen, M. (2008) · Pain · doi:10.1016/j.pain.2007.06.033 · Cited by 230
Zaccara, G., Gangemi, P., Perucca, P., & Specchio, L. (2011) · Epilepsia · doi:10.1111/j.1528-1167.2010.02966.x · Cited by 216
Rintala, D. H., Holmes, S. A., Courtade, D., Fiess, R. N., Tastard, L. V., & Loubser, P. G. (2007) · Archives of Physical Medicine and Rehabilitation · doi:10.1016/j.apmr.2007.07.038 · Cited by 208
Beal, J. E., Olson, R., Lefkowitz, L., Laubenstein, L., Bellman, P., Yangco, B., Morales, J. O., Murphy, R., Powderly, W., Plasse, T. F., et al. (1997) · Journal of Pain and Symptom Management · doi:10.1016/s0885-3924(97)00038-9 · Cited by 206
Pregabalin: latest safety evidence and clinical implications for the management of neuropathic pain
Toth, C. (2014) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098613505614 · Cited by 198
A randomized trial of pregabalin in patients with neuropathic pain due to spinal cord injury
Cardenas, D. D., Nieshoff, E. C., Suda, K., Goto, S.-I., Sanin, L., Kaneko, T., Sporn, J., Parsons, B., Soulsby, M., Yang, R., et al. (2013) · Neurology · doi:10.1212/wnl.0b013e318281546b · Cited by 189
Neuropathic pain in the community: more under-treated than refractory?
Torrance, N., Ferguson, J. A., Afolabi, E., Bennett, M. I., Serpell, M. G., Dunn, K. M., & Smith, B. H. (2013) · Pain · doi:10.1016/j.pain.2012.12.022 · Cited by 188
ROG, D., NURMIKKO, T., & YOUNG, C. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.09.013 · Cited by 187
Safety and efficacy of pregabalin in patients with central post-stroke pain
Kim, J. S., Bashford, G., Murphy, K. T., Martin, A., Dror, V., & Cheung, R. (2011) · Pain · doi:10.1016/j.pain.2010.12.023 · Cited by 143
Vranken, J. H., Hollmann, M. W., van der Vegt, M. H., Kruis, M. R., Heesen, M., Vos, K., Pijl, A. J., & Dijkgraaf, M. G. W. (2011) · Pain · doi:10.1016/j.pain.2010.09.005 · Cited by 137
Norrbrink, C., & Lundeberg, T. (2009) · The Clinical Journal of Pain · doi:10.1097/ajp.0b013e31818a744d · Cited by 133
Sativex long-term use: an open-label trial in patients with spasticity due to multiple sclerosis
Serpell, M. G., Notcutt, W. G., & Collin, C. (2012) · Journal of Neurology · doi:10.1007/s00415-012-6634-z · Cited by 124
Hoggart, B., Ratcliffe, S. H., Ehler, E., Simpson, K. H., Hovorka, J., Lejčko, J., Taylor, L., Lauder, H., & Serpell, M. G. (2014) · Journal of Neurology · doi:10.1007/s00415-014-7502-9 · Cited by 101
Ball, S., Vickery, J., Hobart, J., Wright, D., Green, C., Shearer, J., Nunn, A., Gomez Cano, M., MacManus, D., Miller, D., et al. (2015) · Health Technology Assessment · doi:10.3310/hta19120 · Cited by 78
Cannabinoids: The separation of central from peripheral effects on a structural basis
Evans, F. (1991) · Planta Medica · doi:10.1055/s-2006-960231 · Cited by 76
Vollmer, T. L., Robinson, M. J., Risser, R. C., & Malcolm, S. K. (2014) · Pain Practice · doi:10.1111/papr.12127 · Cited by 65
Flachenecker, P., Henze, T., & Zettl, U. K. (2014) · European Neurology · doi:10.1159/000360285 · Cited by 63
Weber, J., Schley, M., Casutt, M., Gerber, H., Schuepfer, G., Rukwied, R., Schleinzer, W., Ueberall, M., & Konrad, C. (2009) · Anesthesiology Research and Practice · doi:10.1155/2009/827290 · Cited by 56
Cragg, J. J., Warner, F. M., Finnerup, N. B., Jensen, M. P., Mercier, C., Richards, J. S., Wrigley, P. J., Soler, M. D., & Kramer, J. L. K. (2015) · Pain · doi:10.1097/j.pain.0000000000000431 · Cited by 41
The Efficacy of Gabapentin in Patients with Central Post-stroke Pain.
Hesami, O., Gharagozli, K., Beladimoghadam, N., Assarzadegan, F., Mansouri, B., & Sistanizad, M. (2015) · PubMed Central · Cited by 36
Antidepressants Are Effective in Decreasing Neuropathic Pain After SCI: A Meta-Analysis
Mehta, S., Guy, S. D., Lam, T., Teasell, R. W., & Loh, E. (2015) · Topics in Spinal Cord Injury Rehabilitation · doi:10.1310/sci2102-166 · Cited by 29
Paolicelli, D., Direnzo, V., Manni, A., D’Onghia, M., Tortorella, C., Zoccolella, S., Lecce, V. D., Iaffaldano, A., & Trojano, M. (2015) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.670 · Cited by 28
Symptomatic treatment of multiple sclerosis using cannabinoids: recent advances
Smith, P. F. (2007) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.7.9.1157 · Cited by 24
Cited by
Cannabis-based medicines for chronic neuropathic pain in adults
Mücke, M., Phillips, T., Radbruch, L., Petzke, F., & Häuser, W. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012182.pub2 · Cited by 571
Stockings, E., Campbell, G., Hall, W. D., Nielsen, S., Zagic, D., Rahman, R., Murnion, B., Farrell, M., Weier, M., & Degenhardt, L. (2018) · Pain · doi:10.1097/j.pain.0000000000001293 · Cited by 460
Moisset, X., Bouhassira, D., Avez Couturier, J., Alchaar, H., Conradi, S., Delmotte, M. H., Lanteri-Minet, M., Lefaucheur, J. P., Mick, G., Piano, V., et al. (2020) · Revue Neurologique · doi:10.1016/j.neurol.2020.01.361 · Cited by 450
Wang, L., Hong, P. J., May, C., Rehman, Y., Oparin, Y., Hong, C. J., Hong, B. Y., AminiLari, M., Gallo, L., Kaushal, A., et al. (2021) · BMJ · doi:10.1136/bmj.n1034 · Cited by 300
“…et al 2006 Nurmikko et al 2007 Selvarajah et al 2010 Novotna et al 2011 Zajicek et al 2012 Langford et al 2013 Andresen et al 2016 Germini et al 2017 Schimrigk et al 2017 de Vries et al 2017 Subtotal: P=0.021; I2=48.7% Chronic cancer related pain Portenoy et al 2012 Subtotal: P= ; I2= % Overall:…”
BackgroundInfluentialCannabinoid Delivery Systems for Pain and Inflammation Treatment
Bruni, N., Della Pepa, C., Oliaro-Bosso, S., Pessione, E., Gastaldi, D., & Dosio, F. (2018) · Molecules · doi:10.3390/molecules23102478 · Cited by 272
“Although the proportion of patients that showed adverse reactions was higher in dronabinol-treated than in placebo-treated patients, it decreased over the drug’s long-term use [57,58].”
Background
Metadata
- Authors
- Schimrigk, S., Marziniak, M., Neubauer, C., Kugler, E. M., Werner, G., & Abramov-Sommariva, D.
- Affiliations
- Klinikum Lüdenscheid (DE)
- Isar-Amper-Klinikum München-Ost (DE)
- Bionorica (Germany) (DE)
- Venue
- European Neurology
- Publisher
- S. Karger AG
- Published
- 2017
- Volume
- 78
- Issue
- 5-6
- Pages
- 320-329
- ISSN
- 0014-3022 (ISSN-L)
- 1421-9913
- PMC
- PMC5804828
- OpenAlex
- W2765393731
- Cited by
- 136
- References
- 43
- Citations by year
- 2026: 12 · 2025: 9 · 2024: 15 · 2023: 14 · 2022: 37 · 2021: 15 · 2020: 22 · 2019: 6 · 2018: 6
- FWCI
- 6.49
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor)
- creativecommons.org/licenses/by-nc-nd/4.0/ (tdm)
- Locations
- European Neurology (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Bayer Vital
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
- Health Sciences › Medicine › Physiology (medical) › Pain Mechanisms and Treatments
- Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Opioid Use
- Keywords
- dronabinol, neuropathic pain, multiple sclerosis, cannabis-based treatment, long-term treatment safety, adverse drug reactions, drug addiction, pain intensity, risk-benefit ratio
- MeSH terms
- Adult, Double-Blind Method, Female, Humans, Male, Middle Aged, Neuralgia, Dronabinol, Analgesics, Non-Narcotic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.